Vials of the new vaccine being prepared in Italy. Photo: Vincenzo Pinto/AFP via Getty Images In recent weeks, Pfizer and Moderna announced that their coronavirus vaccines have shown extremely promising results. On Monday, it was AstraZeneca’s turn.
Unlike Moderna’s and Pfizer’s vaccines, which use messenger RNA technology, AstraZeneca’s vaccine injects a modified common-cold virus that spurs an immune response if the body detects the coronavirus. When study subjects in Brazil and the U.K. — both of which have seen high levels of COVID in recent months — were given two spaced-out doses, Astra Zeneca’s doses were shown to be 62 percent effective. When given a half-dose followed by a full one, the vaccine was 90 percent effective.
I curb my enthusiasm: The problem of the Oxford vaccine lies in the choice of the vector virus: it is an attenuated, no longer reproducible cold virus that infects chimpanzees. It is not yet used in any approved vaccine. The question of side effects is therefore very sensitive.
zehdeabreu Foi essa que o governo comprou?